Statin therapy and new-onset diabetes: An attempt at recommendations

Expert Review of Endocrinology and Metabolism

Volumn 8, Issue 3, 2013, Pages 213-216

  Banach, Maciej ^a   Mikhailidis, Dimitri P ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

lifestyle changes; new onset diabetes; statin therapy; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 4; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NEW ONSET DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 84877068758     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.13.16     Document Type: Review

References (35)

1. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr. Pharm. Des. PMID: 23278491 (2013) (Epub ahead of print).
2. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and Type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc. Med. J. 5, 24-34 (2011).
3. Otocka-Kmiecik A, Rysz J, Banach M. Prodiabetic effect of statins - do we know the mechanisms of this phenomenon? Postepy Biochem. 58(2), 195-203 (2012).
4. Mikhailidis DP, Elisaf M, Rizzo M et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533-571 (2011).
5. Hsueh WA, Quiñones MJ. Role of endothelial dysfunction in insulin resistance. Am. J. Cardiol. 92(4A), 10J-17J (2003).
6. Zoungas S, Patel A. Cardiovascular outcomes in Type 2 diabetes: the impact of preventative therapies. Ann. NY Acad. Sci. 1212, 29-40 (2010).
7. Sukhija R, Prayaga S, Marashdeh M et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J. Investig. Med. 57(3), 495-499 (2009).
8. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med. Sci. Monit. 15(12), MS1-MS5 (2009).
9. Katsiki N, Banach M. Statin use and risk of diabetes mellitus in postmenopausal women. Clin. Lipidol. 7 267-270 (2012).
10. Rizzo M, Mikhailidis DP. Lipoprotein alterations and reduced growth hormone secretion: relationships with obesity and cardiovascular risk. Clin. Endocrinol. (Oxf.) 76(2), 177-178 (2012).
11. Mäuser W, Perwitz N, Meier B, Fasshauer M, Klein J. Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur. J. Pharmacol. 564(1-3), 37-46 (2007).
12. McGuire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem. Biophys. Res. Commun. 204(1), 399-406 (1994).
13. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J. Pharmacol. Sci. 107(1), 80-89 (2008).
14. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 49(8), 1881-1892 (2006).
15. Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the posttranslational modifications of GTP-binding proteins. Biochem. J. 295 (Pt 1), 31-40 (1993).
16. Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br. J. Pharmacol. 126(5), 1205-1213 (1999).
17. Xia F, Xie L, Mihic A et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 149(10), 5136-5145 (2008).
18. Stepien M, Wlazel RN, Paradowski M et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hyper-tensive patients - pilot study. Arch. Med. Sci. 8(3), 431-436 (2012).
19. Stepien M, Rosniak-Bak K, Paradowski M et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med. Sci. Monit. 17(11), PR13-PR18 (2011).
20. Katsiki N, Banach M. Statins and the risk of diabetes: the debate. Arch. Intern. Med. 172(11), 895-896; author reply 896 (2012).
21. Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375(9716), 735-742 (2010).
22. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170(12), 1024-1031 (2010).
23. Wright JM. Do statins have a role in primary prevention? An update. Ther. Lett. 77, 1-2 (2010).
24. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing Type 2 diabetes: a meta-analysis. Diabetes Care 32, 1924-1929 (2009).
25. Waters DD, Ho JE, DeMicco DA et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J. Am. Coll. Cardiol. 57(14), 1535-1545 (2011).
26. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305(24), 2556-2564 (2011).
27. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380(9841), 565-571 (2012).
28. Watts GF, Ooi EM. Balancing the cardiometabolic benefits and risks of statins. Lancet 380(9841), 541-543 (2012).
29. Waters DD, Ho JE, Boekholdt SM et al. Cardiovascular event reduction versus newonset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J. Am. Coll. Cardiol. 61(2), 148-152 (2013).
30. Wang KL, Liu CJ, Chao TF et al. Statins, risk of diabetes, and implications on outcomes in the general population. J. Am. Coll. Cardiol. 60(14), 1231-1238 (2012).
31. Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch. Intern. Med. 172(2), 144-152 (2012).
32. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
33. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus - a matter for debate. Nat. Rev. Endocrinol. 8(3), 133-134 (2012).
34. Athyros VG, Elisaf MS, Alexandrides T et al.; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 63(5), 358-366 (2012).
35. US FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ ucm293101.htm (Accessed 28 February 2012)